Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.45 |
| ▸ | FPR3 | P25089 | 4/20 | 0.43 |
| ▸ | FPR2 | P25090 | 4/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
| ▸ | POLR1A | O95602 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22341390 | 0.92 | KMT2A (0.54) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL9167791 | 0.86 | KMT2A (0.60) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL17428292 | 0.85 | KMT2A (0.57) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL5654310 | 0.84 | KMT2A (0.62) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL17428293 | 0.84 | KMT2A (0.58) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL166209 | 0.84 | KMT2A (0.56) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL13853727 | 0.83 | KMT2A (0.59) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL12009838 | 0.83 | KMT2A (0.58) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL20852069 | 0.83 | KDM4E (0.58) | KMT2ARAB9AKDM4EALDH1A1LMNA | |
| SCHEMBL20016690 | 0.83 | KMT2A (0.57) | KMT2ARAB9AKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230136702-A1 | Inhibitors of Human Herpesviruses | THE GOVERNORS OF THE UNIVERSTIY OF ALBERTA (CA) | 2023-05-04 | — | — | US | disclosed |
| US-20230136702-A1 | Inhibitors of Human Herpesviruses | THE GOVERNORS OF THE UNIVERSTIY OF ALBERTA (CA) | 2023-05-04 | — | — | US | disclosed |
| WO-2021203028-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-10-07 | — | — | WO | disclosed |
| US-RE47493-E1 | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-09 | — | — | US | disclosed |
| EP-2809652-B1 | ISOQUINOLINE AND NAPHTHYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-05-15 | — | — | EP | disclosed |
| US-9586956-B2 | Isoquinoline and naphthyridine derivatives | GENENTECH, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160318856-A1 | Substituted Urea eIF2alpha Kinase Activators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-11-03 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2016-11-03 | — | — | US | disclosed |
| US-9421211-B2 | N,N′-diarylurea compounds and N,N′-diarylthiourea compounds as inhibitors of translation initiation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-08-23 | — | — | US | disclosed |
| WO-2012162025-A1 | METHODS OF SELECTING CANCER PATIENTS FOR TREATMENT WITH N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120220567-A1 | BENZO-FUSED OXAZEPINE COMPOUNDS AS STEAROYL-COENZYME A DELTA-9 DESATURASE INHIBITORS | SCHERING CORPORATION | 2012-08-30 | — | — | US | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20110144242-A1 | THERMOREVERSIBLY CROSSLINKED ELASTIC BITUMINOUS COMPOSITION | TOTAL RAFFINAGE MARKETING (FR) | 2011-06-16 | — | — | US | disclosed |
| WO-2010138820-A2 | N,N-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008092831-A1 | PTERIDINONE DERIVATIVES AS PI3-KINASES INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-08-07 | — | — | WO | disclosed |
| EP-1953163-A1 | Pteridinone derivatives as PI3-kinases inhibitors | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2008-08-06 | — | — | EP | disclosed |
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160318857-A1 | N,N'-Diarylurea Compounds and N,N'-Diarylthiourea Compounds as Inhibitors of Translation Initiation | NSUN2, EIF2AK2, RNGTT | KMT2A 761/4885RAB9A 2490/4885KDM4E 1117/4885 |
| US-20120220567-A1 | BENZO-FUSED OXAZEPINE COMPOUNDS AS STEAROYL-COENZYME A DELTA-9 DESATURASE INHIBITORS | SCD, SCD5, CPT1A | KMT2A 2057/4885RAB9A 2573/4885KDM4E 898/4885 |
| US-20230136702-A1 | Inhibitors of Human Herpesviruses | RPL5, RPL35, HAVCR2 | KMT2A 329/4885RAB9A 2843/4885KDM4E 85/4885 |
| US-20160318856-A1 | Substituted Urea eIF2alpha Kinase Activators | EIF2AK1, EIF2A, EIF4A2 | KMT2A 635/4885RAB9A 1341/4885KDM4E 872/4885 |
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | KCNN3, KCNN1, KCNN2 | KMT2A 1235/4885RAB9A 2665/4885KDM4E 722/4885 |
| US-20110144242-A1 | THERMOREVERSIBLY CROSSLINKED ELASTIC BITUMINOUS COMPOSITION | F2, H1-0, FASN | KMT2A 2056/4885RAB9A 3540/4885KDM4E 3170/4885 |
| US-20120115915-A1 | N,N'-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | NSUN2, EIF2AK2, RNGTT | KMT2A 761/4885RAB9A 2490/4885KDM4E 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.